Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Appears Gap around 0.29 is Filling Now (EOM)
View:
Post by Scorpio2 on Aug 25, 2022 2:18pm

Appears Gap around 0.29 is Filling Now (EOM)

If it has to be done, get her done asap. Never could understand the idiocy of gap fills. Sounds like another tool for brokers to justify their manipulation of a stock's price (for their benefit alone).
Comment by DJDawg on Aug 25, 2022 2:21pm
Dumb question - what is a gap fill? What did it it "have to happen"
Comment by Yoly900 on Aug 25, 2022 2:27pm
I believe we close 0.29 US Side today Tom 34-35 
Comment by Yoly900 on Aug 25, 2022 2:30pm
I also believe this sell off means bad news absolutely wait another 1-2 years until they have this right way 
Comment by Rumpl3StiltSkin on Aug 25, 2022 2:41pm
What?? Lol.
Comment by ScienceFirst on Aug 25, 2022 2:44pm
In Yoly900, we officially have our first short!  I was wondering when we would have it.  It's now official. We see this can of profiles on many boards (PYR, HPQ, etc ...).   Expect him to post 100% negative stuff here, just to play FUD.  It's probably because this clown wants your shares on the cheap and has been told about the potential of our technology, so our ...more  
Comment by Rumpl3StiltSkin on Aug 25, 2022 2:58pm
Hmm, nice chunk of shares sitting there at .30c... If someone wanted to build their position.
Comment by Eoganacht on Aug 25, 2022 3:08pm
He created a Stockhouse user today so he could share his negativity with us :)
Comment by Rumpl3StiltSkin on Aug 25, 2022 3:14pm
Try as they might, they never get any of us longs to part with shares....
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250